Vixiar Medical
Paul Robberts has extensive experience in various leadership roles across multiple sectors, particularly in pharmaceuticals and real estate. Currently serving as a board member at Kamer van Gerlach since September 2021, Robberts is also a managing partner at Cresco Pharma B.V. since 2007, focusing on pharmaceutical projects including antibiotics and Parkinson's disease treatments. Robberts holds the position of seed funder at Vixiar Medical and is a partner at Maatschap "Heeren van Oranje," which manages real estate portfolios. Additional roles include managing director at Kacero Holding, specializing in real estate management and venture capital, and as DGA at Robotronics BV, focusing on specialized medical equipment. Previous experience includes directorship at Syrolab BV and involvement in new business development at Mediq BV. Educational background includes a degree in Gymnasium bèta from Delft University of Technology and Stella Maris College Meerssen.
This person is not in any teams
This person is not in any offices
Vixiar Medical
Vixiar Medical, Inc. is a Maryland company founded to commercialize unique technologies for the non-invasive monitoring of cardiopulmonary diseases, particularly those with a significant clinical and economic burden. The Company’s first product, Indicor ™, has been licensed from Johns Hopkins University and is a portable, hand-held device for assessing cardiac filling pressures for monitoring congestive heart failure (HF) at the point of care in hospitals, physician’s offices, nursing facilities and other clinical settings. The device is an alternative to more labor intensive, more expensive, invasive or less accurate approaches and is designed to prevent hospital readmissions and improve clinical management of HF.